CN1565483A - Medicine for treating chronic and refractory primary thrombocytopenic purpura - Google Patents
Medicine for treating chronic and refractory primary thrombocytopenic purpura Download PDFInfo
- Publication number
- CN1565483A CN1565483A CNA031125425A CN03112542A CN1565483A CN 1565483 A CN1565483 A CN 1565483A CN A031125425 A CNA031125425 A CN A031125425A CN 03112542 A CN03112542 A CN 03112542A CN 1565483 A CN1565483 A CN 1565483A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- mixture
- present
- medicine
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a medicine for treating chronic and refractory primary thrombocytopenic purpura, which is prepared from Chinese medicinal herbs including Chinese angelica root, wolferry fruit, garden burnet root, polygala root, arborviate seed, fragrant solomonseal rhizome, radix adenophorae and donkey-hide gelatin by proportion.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of chronic and intractable idiopathic thrombocytopenic purpura, especially is the pure Chinese medicine medicine that raw material is made with the Chinese herbal medicine.
Background technology
Idiopathic thrombocytopenic purpura (ITP) is common clinically hemorrhage, and this disease principal character is a thrombocytopenia, and the bleeding time prolongs, skin and mucosa petechia or ecchymosis, hematoma, and severe patient can have symptoms such as gastrointestinal tract and urinary tract are hemorrhage.Can be divided into acute and chronic type according to the state of an illness.Acute idiopathic thrombocytopenic purpura may be relevant with viral infection, often betide and infected the back 2～21 days, see with the child more, onset is hurried, and serious thrombocytopenia and bleeding are arranged, and about half 6 weeks of acute ITP patient, interior platelet recovery was normal, cure in 80%～90% half a year, the minority case presents outbreak repeatedly, and 10% transfers chronic type to, has 1% patient dead because of intracranial hemorrhage approximately.Chronic idiopathic thrombocytopenic purpura (CITP) is more common in the young woman for a kind of primary disease of adult, generally seldom spontaneous remission, and the course of disease is longer, can reach 1 year to the several years, even many decades.Outbreak replaces with alleviation, is acute attack sometimes, and its mortality rate is about 3.9%～4.4%, and intracranial hemorrhage still is the main cause of death.The CITP that Drug therapy is invalid and splenectomy is invalid such as adrenal gland's glucocorticoid are called intractable ITP again, and mortality is up to 16.6%.
At present, domestic and international Therapeutic Method to chronic and intractable idiopathic thrombocytopenic purpura has chemotherapy, Chinese medicine Coryza Treated by Syndrome Differentiation and splenectomy treatment.These treatments have run into following thorny problem:
1. chemotherapy is main treatment means with immunosuppressant such as adrenal gland's glucocorticoids, in recent years, adopt heavy dose of intravenous drip immunoglobulin, platelet transfusion, tamoxifen and various neotype immunosuppressant such as cyclophosphamide, Ciclosporin A, vincristine, vindesine etc. to begin to be applied to clinical, but the application of these chemicalses does not all make the treatment generation essence of chronic and intractable ITP take on a new look, and cost an arm and a leg, toxic and side effects is bigger, and patient has is difficult to accept.1. adrenal gland's glucocorticoid: be the choice drug of treatment primary disease, acute ITP is also had certain curative effect, effective percentage reaches 70%～90% in the recent period, and complete remission rate is 29.5%, but easily recurrence after the drug withdrawal.The prolonged application untoward reaction is more, as Ke Xing face, hypertension, water-sodium retention, hyperchlorhydria, osteoporosis, hypokalemia, hyperglycemia, hormonal psychosis and adrenal cortex atrophy etc.2. immunoglobulin'intravenous (IVIg): comprehensive some scholar's clinical report results, stable remission rate only is 5%～10%, and has 10%～20% patient drug resistance can occur.Untoward reaction has headache, discomfort and phlebitis etc.3. interferon (INF): external successively have the scholar to observe INF to treat intractable ITP part effectively, but indivedual report has and causes serious upper gastrointestinal hemorrhage and intracranial hemorrhage phenomenon.4. Ciclosporin A (cyclosporin A, CyA): be potent immunosuppressant, abroad begun since the nineties to attempt with the chronic and intractable ITP of CyA treatment.Emilia in 1996 etc. have observed the curative effect of patient's prolonged application CyA of 8 routine intractable autoimmune diseasees, follow up a case by regular visits to 13～62 months, and wherein 3 routine patients are alleviated fully, and 2 routine patients are partly alleviated.Untoward reaction mainly contains that upper abdomen is glutted, loss of appetite, hepatic and renal function are impaired, hirsutism and secondary tumors.5. danazol (Danazol): effective percentage is about 25.5%～61.9%, easily recurrence after the drug withdrawal.Main adverse reaction has hemorrhagic cystitis, bone marrow depression, alopecia, liver function damage etc.6. cyclophosphamide: remission rate 23.6%～45%.Untoward reaction comprises bone marrow depression, alopecia, hemorrhagic cystitis, liver function damage, infertile, secondary tumors and acute leukemia.7. azathioprine: remission rate only is 12.0%, and untoward reaction has bone marrow depression, anorexia, feels sick, vomiting, secondary tumors such as lymphoma.8. vincristine (VCR): consumption is 1～2mg weekly, 3～6 weeks of the course of treatment, vein slowly instils, can make rapid, the temporary transient improvement of about half ITP patient platelet, complete remission rate only is 5%～10%, untoward reaction comprises serious hypotension and heating, also has neuritis, agranulocytosis, leukopenia, hepatitis, alopecia, constipation etc.If medicinal liquid spills blood vessel, can cause local tissue necrosis.
In addition, medicines such as vindesine, antilymphocyte globulin, levamisole, tire flesh liquid, tamoxifen also can be treated chronic and intractable ITP, but equal not agreeing property curative effects, and also exist certain untoward reaction.
2. splenectomy: bigger to patient trauma, remission rate only is a relapse rate 26.87% after 50%～80%, a year, after the recurrence again remission rate be about 58%.
3. Chinese medicine Coryza Treated by Syndrome Differentiation: determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs is the characteristic of Chinese traditional treatment disease, has embodied the flexible principle that Chinese traditional treatment varies with each individual.Clinically general chronic and intractable ITP is divided into bleeding due to blood-heat, hyperactivity of fire caused by deficiency of YIN, QI failing to control blood, obstruction of collaterals by blood stasis four types.Yin Yan serves as basis side's plus-minus with the alizarin mixture of purple, treats chronic and intractable ITP82 example altogether, total effective rate 78%, and platelet count has significant difference before and after treatment; Zhang Gengli is divided into hyperactivity of fire caused by deficiency of YIN regulating YIN and YANG deficiency with primary disease, and type of hyperactivity of fire caused by deficiency of YIN is with the treatment of YIN nourishing removing heat from blood side, and the deficiency of both YIN and YANG type is treated with temperature male wind-supplying kidney side, treat the ITP34 example altogether, type of hyperactivity of fire caused by deficiency of YIN 15 examples wherein, effective 10 examples, deficiency of both YIN and YANG type 19 examples, effective 16 examples, total effective rate 83.3%; Cao Xuejun is divided into cloudy bright excess-heat, bleeding due to blood-heat with chronic and intractable ITP, deficiency of kidney yin, hyperactivity of fire caused by deficiency of YIN, impairment caused by overstrain heart spleen, failure of the spleen to keep the blood flowing within the vessels, stagnation of QI due to depression of the liver four types, cloudy bright excess-heat, bleeding due to blood-heat type are treated with Huaban Tang, xijiao Dihuang Tang, yun, deficiency of kidney yin, type of hyperactivity of fire caused by deficiency of YIN close ZHIBAIDIHUANG Tonga with ERZHI WAN and subtract treatment, deficiency of spleen-QI, QI failing to control blood type are treated with Radix Ginseng GUIPI TANG plus-minus, stagnation of QI due to depression of the liver, qi stagnation and blood stasis type are treated with 'Xue Fu Zhu Yu ' Tonga Radix Notoginseng powder, treat chronic and intractable ITP69 example altogether, total effective rate 81%.
Summary of the invention
Technical problem to be solved by this invention provides a kind of concordance curative effect that has, and no obvious toxic-side effects is cheap, and no rebound phenomenon takes place after the drug withdrawal, is used for the treatment of the pure Chinese medicine medicine of chronic and intractable ITP.
Solution of the present invention is: by secular clinical observation and deep analysis and research, achievement according to theory of Chinese medical science and modern Chinese medicine pharmacological research, analyze experience and the deficiency of the chronic and intractable ITP of integrative therapy, start with from the cause of disease that solves chronic and intractable ITP patient, use QI invigorating, enrich blood, the kidney invigorating, YIN nourishing, calm the nerves, medicines such as removing heat from blood, hemostasis, formed the medicine that pure Chinese medicine is made.
The present invention is achieved in that a kind of medicine for the treatment of chronic and intractable idiopathic thrombocytopenic purpura, and it is the medicament of being made by the following weight proportion raw material
Radix Angelicae Sinensis 12～22 weight portions
Fructus Lycii 12～20 weight portions
Radix Sanguisorbae 12～20 weight portions
Radix Polygalae 12～16 weight portions
Semen Platycladi 12～16 weight portions
Rhizoma Polygonati Odorati 12～18 weight portions
Radix Adenophorae (Radix Glehniae) 12～18 weight portions
Colla Corii Asini 12～16 weight portions.
The production method that above-mentioned each component is made mixture is: above-mentioned raw materials elder generation water is cleaned one time, after being soaked in water 1 hour, decocted 0.5～1 hour again, the gained medicinal liquid is poured out, in raw material, add water again, decocted 0.5～1 hour, pour out medicinal liquid, decoct with water again, decoct altogether three times, the medicinal liquid that will decoct three times gained merges, filters, with the decoction liquor of the raw material gained of every 100g weight, simmer down to 190～210ml makes the mixture of the present invention's medicine.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1. the present invention selects natural Chinese medicine for use, does not add any additives, utilizes the comprehensive function of each medicine, and is to immune two-ways regulation, nontoxic to human body.
2. drug oral free from extraneous odour of the present invention, taking convenience.
3. prescription on individual diagnosis person uses this medicine separately and gets final product for the first time.The person that uses the other drug during prescription on individual diagnosis, when using this medicine, can be according to the state of an illness, administration time and the former medicament categories of using, the drug withdrawal immediately or the former medicine of using of stopping using gradually.
4. curative effect of medication of the present invention is good, and effective percentage reaches 100%, and does not have the drug withdrawal rebound phenomenon.
5. medicine expense of the present invention is cheap, and short treating period is cured and recovery platelet count＞100 * 10
9The required natural law of/L is 6～34 days, average 21 days.
The specific embodiment
Further specify the present invention below.
For showing the therapeutic effect of medicine of the present invention to chronic and intractable ITP, inquire into its treatment mechanism, the mixture that we make with the present invention's medicine (hereinafter to be referred as the present invention's mixture) is an example, studies from basic pharmacology and clinical practice two aspects.
One, basic pharmacological experiments shows:
(1) gastrointestinal administration is to the influence of mice peripheral blood platelet number (BPC): the result proves that the large and small dosage group of the present invention's mixture, prednisone group all can obviously promote the periphery BPC of mice, with normal saline group comparison difference have the highly significant meaning (
*P＜0.01); Large and small dosage the present invention's mixture group and prednisone compare, and difference does not have significance (#P＞0.05).Large and small dosage the present invention's mixture group is compared, and difference does not have significance meaning (P＞0.05).
Table 1 the present invention's mixture is to the influence of mice peripheral blood platelet number
Drug dose number of animals BPC (* 10
9/ L) platelet increases
Group
(/kg) (only) X ± S (%)
Normal saline 20ml 10 679.9 ± 84.9-
Prednisone 50mg 10 1024.2 ± 114.1** 58%
Mixture 25g 10 1135.2 ± 133.0**# 67% of low dose of the present invention
Mixture 50g 10 1148.3 ± 110.5**# 68.9% of heavy dose of the present invention
Annotate: t check, * * P＜0.01, #P＞0.05, P＞0.05
(2) gastrointestinal administration is to the influence of rabbit platelet count (BPC): the result shows that the present invention's mixture can promote normal rabbits peripheral blood platelet number, compares with matched group, and difference has highly significant meaning (P＜0.01).
Table 2 the present invention's mixture is to the influence of rabbit platelet count
Drug dose number of animals BPC (* 10
9/ L) platelet increases
Group
(/kg) (only) X ± S (%)
Normal saline 8ml 6 226.5 ± 35.17-
Mixture 10g 6 344.5 ± 39.10** 52% of the present invention
Annotate: the t check,
*P＜0.01
(3) the present invention's mixture is right
60The effect of the animal model of thrombocytopenia due to the Co irradiation: by table 3 as seen, the present invention's mixture group with
60Co irradiation+normal saline group compares, and difference has highly significant meaning (##P＜0.01), compares with the normal saline group, and difference does not have significance (P＞0.05); And
60Co irradiation+normal saline group and normal saline group relatively, difference have the highly significant meaning (
*P＜0.01).The experimental result explanation,
60The animal model of thrombocytopenia is successful due to the Co irradiation, and the present invention's mixture is right
60The pathological model of thrombocytopenia has good protective action due to the Co irradiation.
Table 3 the present invention's mixture is right
60The thrombocytopenic influence of Co irradiation induced mice
Drug dose number of animals BPC (* 10
9/ L) platelet increases
Group
(kg) (only) X ± S (%)
Normal saline 20ml 10 766.9 ± 109.3-
60Co+ normal saline 20ml 10 509.7 ± 70.20**-33.5%
60Mixture 25g 10 805.9 ± 115.7## 5.1% of Co+ the present invention
Annotate: the t check, the present invention's mixture group and normal saline group compare, P＞0.05, with
60Co irradiation+normal saline group compares, ##P＜0.01; The normal saline group with
60Co+ normal saline group compares,
*P＜0.01
(4) gastrointestinal administration is to the influence of clotting time of mice (CT): the present invention's mixture is compared with the etamsylate group, and difference does not have significance (P＞0.05), with the normal saline matched group relatively, difference have the highly significant meaning (
*P＜0.01); The etamsylate group is compared with the normal saline group, and difference has highly significant (##P＜0.01).
Table 4 the present invention's mixture is to the influence of clotting time of mice
Drug dose number of animals clotting time (S) shortens clotting time
Group
(/kg) (only) X ± S (%)
Normal saline 20ml 10 132 ± 18-
Etamsylate 0.5mg 10 52 ± 12## 60.6%
Mixture 25g 10 48 ± 17** 63.6% of the present invention
Annotate: the present invention's mixture group and normal saline group compare,
*P＞0.05 is compared with the etamsylate group in P＜0.01; Etamsylate group and normal saline group compare, ##P＜0.01
(5) gastrointestinal administration is to the influence of mice bleeding time (BT): the present invention's mixture and carbazochrome salicylate group relatively, difference does not have significance (P＞0.05), with the normal saline matched group relatively, difference have highly significant (
*P＜0.01): carbazochrome salicylate group and normal saline group compare, and difference has highly significant (##P＜0.01).
Table 5 the present invention's mixture is to the influence in mice bleeding time
Drug dose number of animals clotting time (S) shortens clotting time
Group
(/kg) (only) X ± S (%)
Normal saline 20ml 10 483 ± 68-
Carbazochrome salicylate 15mg 10 201 ± 41## 58.2%
Mixture 25g 10 192 ± 57** 60.2% of the present invention
Annotate: the present invention's mixture group and normal saline group compare,
*P＜0.01; Compare P＞0.05 with the carbazochrome salicylate group; Carbazochrome salicylate group and normal saline group compare, ##P＜0.01
(6) the present invention's mixture is to the influence of rabbit bone marrow megakaryocyte differentiation: the present invention's mixture group bone marrow produces template megalokaryocyte and the total percentage ratio of megalokaryocyte, is significantly higher than matched group, meaning that there was a significant difference (
*P＜0.05), illustrates that the present invention's mixture has the effect of promotion megalokaryocyte differentiation and maturation.
Table 6 the present invention's mixture is to the influence of rabbit bone marrow megakaryocyte
The drug dose number of animals is produced the template macronucleus and is accounted for megalokaryocyte
Group
The total percentage ratio of (/kg) (only) (X ± S)
Normal saline 8ml 6 22.5% ± 1.98%
Mixture 10g 6 33.5% ± 2.95%* of the present invention
Annotate: the t check,
*P＜0.05
(7) proliferation of bone marrow cells reaction: by table 7 as seen, the present invention's mixture can promote the proliferation of bone marrow cells reaction, compares meaning that there was a significant difference (* P＜0.05) with the normal saline matched group.
Table 7 the present invention's mixture is to the influence of proliferation of bone marrow cells
Drug dose number of animals proliferation of bone marrow cells (OD)
Group
(/kg) (only) (X ± S)
Normal saline 20ml 10 0.464 ± 0.0544
Mixture 25g 10 0.574 ± 0.0545* of the present invention
Annotate: the t check,
*P＜0.05
(8) lymphocyte transformation function test: as seen by table 8, the present invention's mixture can make PHA activated lymphocytes conversion ratio improve, compare with the normal saline matched group, difference has highly significant meaning (* * * P＜0.001), illustrates that the present invention's mixture can significantly strengthen cellular immune function.
Table 8 the present invention's mixture is to the influence of lymhocyte transformation rate
Drug dose number of animals lymphocyte transformation percentage rate
Group
(/kg) (only) (X ± S)
Normal saline 20ml 10 34.2% ± 2.76%
Mixture 25g 10 62.2% ± 3.98%*** of the present invention
Annotate: the t check,
* *P＜0.001
(9) lymphproliferation response: as seen by table 9, the present invention's mixture can strengthen the splenic lymphocytes of normal mouse, the T lymphproliferation response that ConA is excited is obvious, compare with the normal saline matched group, difference has highly significant meaning (* * P＜0.01), illustrates that the present invention's mixture can significantly strengthen cellular immune function.
Table 9 the present invention's mixture is to the influence of spleen lymphocyte proliferation
Group drug dose number of animals spleen lymphocyte proliferation (OD)
(/kg) (only) (X ± S)
Normal saline 20ml 10 0.56 ± 0.0533
Mixture 25g 10 0.718 ± 0.0912** of the present invention
Annotate: the t check,
*P＜0.01
(10) the peritoneal macrophage phagocytic function detects: by table 10 as seen, the present invention's mixture can improve peritoneal macrophage and engulf the chicken red blood cell percentage rate, compare with the normal saline matched group, difference has highly significant meaning (* * P＜0.01), illustrates that it can significantly improve the mice non-specific immunity.
Table 10 the present invention's mixture is to the influence of peritoneal macrophage phagocytic rate
Drug dose number of animals phagocytic rate (%)
Group
(/kg) (only) (X ± S)
Normal saline 20ml 10 27.9 ± 6.40
Mixture 25g 10 39.1 ± 3.80** of the present invention
Annotate: the t check,
*P＜0.01
(11) are haemolysis spectrophotometry (QHS) quantitatively: the result shows, the present invention's mixture group antibody generates and reduces, compare with the normal saline matched group, meaning that there was a significant difference (* P＜0.05), prompting the present invention's mixture is inhibited to humoral immunization.
The influence that table 11 the present invention's mixture antagonist forms
Group drug dose number of animals half hemolysis value (HC
50)
(/kg) (only) (X ± S)
Normal saline 20ml 10 272.4 ± 25.3
Mixture 25g 10 201.6 ± 20.9* of the present invention
Annotate: the t check,
*P＜0.05
By above experiment, can draw to draw a conclusion:
1. the present invention's mixture can promote bone marrow cells in mice propagation, and the differentiation that promotes the rabbit bone marrow megakaryocyte promotes the peripheral blood platelet number with ripe; And it is right
60The thrombocytopenia animal model has good protective action due to the Co irradiation.
2. the present invention's mixture can shorten that normal mouse goes out, clotting time.
3. the present invention's mixture can strengthen nonspecific immunity and the cellular immune function of mice, suppresses humoral immune function, has immune opsonic action (dual regulation).
4. the present invention's mixture to the possible mechanism of action for the treatment of chronic and intractable ITP is: 1. by stimulating bone marrow, promote the differentiation and development of hematopoietic stem cell; Promote bone marrow to produce the Megakaryocytic differentiation of template with ripe, platelet is generated to be increased.2. by suppressing the generation of antiplatelet antibody, reduce platelet destruction, promote the peripheral blood platelet number.3. immune opsonic action: the present invention's mixture can suppress humoral immune function by improving cellular immune function, corrects chronic and intractable ITP patient's immunoregulatory disorder state.
Two, clinical observation material
1.1 case: select outpatient service and inpatient, selected case all meets the chronic and intractable ITP diagnostic criteria in " hematopathy diagnosis and criterion of therapeutical effect ", that is: 1. extensive hemorrhage skin, mucosa and the internal organs of involving.2. many lab testing platelet counts reduce.3. spleen does not increase or only slightly increases.4. bone marrow examination megalokaryocyte number increases or normally, dysmaturity is arranged.5. should have wherein one in following five: the treatment of (1) prednisone effectively; (2) the splenectomy treatment effectively; (3) PAIg increases; (4) PAC
3Increase; (5) life-span determination of blood platelet shortens; 6. eliminating secondary thrombocytopenia.Have 102 examples, male's 43 examples wherein, women's 59 examples, 11～57 years old age, the course of disease 5 months～6 years all adopts Drug therapys such as adrenal gland's glucocorticoid, immunoglobulin, platelet transfusion, large doses of vitamin C invalid, wherein has 22 examples to be not suitable for or patient disagrees with and does splenectomy, invalid after the 3 routine splenectomy, use this mixture treatment instead.
1.2 administrated method: take the present invention's mixture 150ml, 3 times on the one, serveing on 10 days is a course of treatment at every turn, and children's is cut down according to the circumstance.The medicines such as prednisone of slowly stopping using during the medication, have according to the state of an illness any medicine of can stopping using.
1.3 observation index: disappear situation, appetite and the mental status etc. such as situation, mucosal bleeding such as gingiva oozing of blood of platelet counts and patient's skin purpura in the check blood before and after the treatment.
2.1 curative effect judging standard is divided into according to " hematopathy diagnosis and criterion of therapeutical effect ":
Produce effects: platelet recovery is normal, and no bleeding continues more than 3 months.Keeping more than 2 years no recidivist cures for basic.
The good effect: platelet rises to 50 * 10
9/ L or more former level rise 30 * 10
9More than/the L, do not have or do not have substantially bleeding, continue more than 2 months.
Progressive: platelet rises to some extent, and bleeding improves, and continues more than 2 weeks.
Invalid: platelet count and bleeding do not have improvement or worsen.
2.2 total effects: 102 routine patients, cure 30 examples substantially, produce effects 48 examples are very imitated 24 examples, total effective rate 100%.
2.3 bleeding complete obiteration natural law: cured elder substantially 26 days, average 18 days; Produce effects and very imitated elder 34 days, the shortest person 16 days, average 27.5 days.
2.4 cure and recovery platelet count＞100 * 10
9/ L required time is 6～34 days, average 21 days
2.5 platelet count behind the base therapy: basic healing is (126.5 ± 11.3) * 10 with the produce effects case
9/ L on average rises 78.9 * 10
9/ L.
Embodiment: take by weighing raw material by following proportioning:
Radix Angelicae Sinensis 18g Fructus Lycii 18g Radix Sanguisorbae 12g
Radix Polygalae 12g Semen Platycladi 12g Rhizoma Polygonati Odorati 16g
Radix Adenophorae (Radix Glehniae) 16g Colla Corii Asini 12g
Above-mentioned raw materials elder generation water is cleaned one time, after being soaked in water again 1 hour, decocted 0.5～1 hour, the gained medicinal liquid is poured out, in raw material, add water again, decocted 0.5～1 hour, and poured out medicinal liquid, decoct with water again, decoct altogether three times, the medicinal liquid that decocts three times gained is merged, filters,, make the mixture of the present invention's medicine decoction liquor simmer down to 230ml.
Chronic and intractable ITP, because the course of disease is longer, all experienced the treatment of immunosuppressant such as secular heavy dose of adrenal gland's glucocorticoid and other medicines, that have even implemented the splenectomy operation, patient all shows the traditional Chinese medical science said " deficiency syndrome ", mainly show as cardiopalmus, breathe hard, weak, lethargy, depressed, poor sleep, inappetence etc., therefore, we have selected Radix Adenophorae (Radix Glehniae), Rhizoma Polygonati Odorati, Colla Corii Asini, Fructus Lycii for use, when being classified as the master, give YIN nourishing, QI invigorating, enrich blood, the kidney invigorating, with deficiency syndrome symptoms such as eliminating patient and breathe hard, weak; Be aided with Radix Polygalae, Semen Platycladi nourishing blood to tranquillize the mind, eliminate symptoms such as patient's anxiety, insomnia; Be equipped with hemostasis, removing heat from blood such as Radix Sanguisorbae, eliminate patient's diseases such as hemorrhage, purpura, thereby present ideal therapeutic effect.
Modern single medicinal material research confirms, Radix Angelicae Sinensis in the prescription can significantly strengthen the phagocytic function of peritoneal macrophage to chicken red blood cell, improve the clean up speed of reticuloendothelial system to dyestuff, immunosuppressive action due to the 17-hydroxy-11-dehydrocorticosterone is had antagonism, illustrate that it can promote non-specific immunity; Document announcement is arranged, and Radix Angelicae Sinensis can promote humoral immune function, and document announcement is also arranged, and it is to suppress humoral immune function; Can obviously promote the DNA and proteinic the synthesizing of the inductive mouse spleen lymphocyte of ConA, and lymphocyte is had stronger activation, illustrate that it can improve the body cell immunologic function; Mice pluripotential hemopoietic stem cell (CFU-S) to normal or radiation damage all has the promotion proliferation function, can significantly promote the recovery of bone marrow and splenocyte hemopoietic function.Fructus Lycii in the prescription can obviously strengthen the phagocytic function of Turnover of Mouse Peritoneal Macrophages, strengthens the phagocytic activity of reticuloendothelial system to india ink, the enhancing non-specific immunity function; Immunne response to the antigenic immunne response of TD and IgG, IgE antibody has tangible potentiation, and can increase the T of immunosuppressant animal
HCell number improves T
H/ T
SRatio, strengthen humoral immunization and cellular immune function: report is arranged, Fructus Lycii lyophilized powder suspension energy antagonism cyclophosphamide suppresses the effect of hemopoietic function of bone marrow, rat test finds that lycium barbarum polysaccharide is when strengthening splenocyte propagation, the spleen norepinephrine obviously descends, the content of hypothalamus norepinephrine, dopamine, 5-hydroxy tryptamine also descends, the plasma corticosterone level reduces, think that thus the agency part of Fructus Lycii raise immunity is to realize by the sympathetic nerve of regulating hypothalamus, immune organ and through the mutual coordination of adrenal cortex function; In addition, Fructus Lycii still has short gonad function effect, and it is useful that yang deficiency patient is recovered the normal physiological regulatory function.Radix Adenophorae (Radix Glehniae) in the prescription forms cell number for SRBC immune mouse spleen hemolysis plaque remarkable inhibitory action, and injection can significantly suppress the generation of SRBC induced mice serum agglutinin antibody before sensitization; Human peripheral lymphocytes conversion under PHA, the ConA stimulation also is inhibitory action, illustrate that it all has the obvious suppression effect to specific humoral immunity and cellular immunization, because of YIN nourishing power is strong, the Chang Zuowei yin-nourishing drug is used for the treatment of yin deficiency syndrome and autoimmune disease.Colla Corii Asini in the prescription can make hemoglobin, erythrocyte, leukocyte, platelet all obviously increase, and this effect may have substantial connection to the facilitation of the histo-differentiation of hematopoietic stem cell and hemopoietic system with contained collagen protein, glycosaminoglycan; Can improve Turnover of Mouse Peritoneal Macrophages phagocytic percentage and phagocytic index, natural killer cell is had facilitation, promote healthy human lymphocyte to transform, improve body's immunological function; Can also obviously improve
60CO irradiation mice survival rate has good radiation resistance.The result of these modern studies exactly with the prescription of medicine of the present invention according to matching.
Claims (3)
1, a kind of medicine for the treatment of chronic and intractable idiopathic thrombocytopenic purpura is characterized in that, it is the medicament of being made by the following weight proportion raw material
Radix Angelicae Sinensis 12～22 weight portions
Fructus Lycii 12～20 weight portions
Radix Sanguisorbae 12～20 weight portions
Radix Polygalae 12～16 weight portions
Semen Platycladi 12～16 weight portions
Rhizoma Polygonati Odorati 12～18 weight portions
Radix Adenophorae (Radix Glehniae) 12～18 weight portions
Colla Corii Asini 12～16 weight portions.
2, a kind of medicine for the treatment of chronic and intractable idiopathic thrombocytopenic purpura as claimed in claim 1 is characterized in that wherein the weight proportion of each raw material is
Radix Angelicae Sinensis 18 weight portions
Fructus Lycii 18 weight portions
Radix Sanguisorbae 12 weight portions
Radix Polygalae 12 weight portions
Semen Platycladi 12 weight portions
Rhizoma Polygonati Odorati 16 weight portions
Radix Adenophorae (Radix Glehniae) 16 weight portions
Colla Corii Asini 12 weight portions.
3, a kind of medicine for the treatment of chronic and intractable idiopathic thrombocytopenic purpura as claimed in claim 1 or 2 is characterized in that, described medicament is a mixture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031125425A CN1234394C (en) | 2003-06-14 | 2003-06-14 | Medicine for treating chronic and refractory primary thrombocytopenic purpura |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031125425A CN1234394C (en) | 2003-06-14 | 2003-06-14 | Medicine for treating chronic and refractory primary thrombocytopenic purpura |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1565483A true CN1565483A (en) | 2005-01-19 |
| CN1234394C CN1234394C (en) | 2006-01-04 |
Family
ID=34468937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031125425A Expired - Fee Related CN1234394C (en) | 2003-06-14 | 2003-06-14 | Medicine for treating chronic and refractory primary thrombocytopenic purpura |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1234394C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953936A (en) * | 2010-09-19 | 2011-01-26 | 姜红 | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof |
-
2003
- 2003-06-14 CN CNB031125425A patent/CN1234394C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953936A (en) * | 2010-09-19 | 2011-01-26 | 姜红 | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof |
| CN101953936B (en) * | 2010-09-19 | 2012-11-07 | 李西爱 | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1234394C (en) | 2006-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN1167454C (en) | Chinese medicine for detoxication purpose and its preparing process | |
| CN1686506A (en) | Medicine for treating mammary gland proliferation, its preparation method and application | |
| CN1965990A (en) | Medicament for preventing and treating benign hyperplasia of mammary glands in women and preparation process thereof | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1621080A (en) | Medicine for abstaining from drug addiction and its preparation | |
| CN1850255A (en) | Medicine composition and preparing method | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1234394C (en) | Medicine for treating chronic and refractory primary thrombocytopenic purpura | |
| CN1718193A (en) | Total secondary ginseng glucoside medicine composition, its prepn. method and application in preparing medicine for treating myocardial ischemia and hemorrhagic shock | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN1424057A (en) | Chinese medicine immunomodulator and its preparation method and use in pharmacy | |
| CN1293896C (en) | Medication for treating primary disease of purpura haemorhagica and preparation method | |
| CN1456198A (en) | Angong hemostatics | |
| CN1593493A (en) | Therapy assisting agent and its preparation | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| CN1541691A (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1323679C (en) | Medicine for treating enteron diseases | |
| CN1278734C (en) | Pharmaceutical composition for stopping drug addiction and its preparing process | |
| CN1234403C (en) | Chinese medicine for treating gastric disease | |
| CN1158099C (en) | Medicine for treating osteoarthritis and its preparing process and application | |
| CN1178690C (en) | Medicine for regulating immunity and its production method | |
| CN1246012C (en) | Medicine for treating endometriosis and its preparing process | |
| CN1931256A (en) | Chinese medicine capsule for eliminating drug addiction and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |